SMAD3 and neoplasm: We demonstrate that therapeutical intervention on the transcriptional pathways mediated by AP‐1, SMAD3 and RUNX1/RUNX2, combined with the GBM standard‐of‐care treatment based on temozolomide, led to the pronounced impairment of tumour growth, which was more evident in the context of the MS‐like subtype.